<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566267</url>
  </required_header>
  <id_info>
    <org_study_id>00887</org_study_id>
    <secondary_id>MIRB Number: 00887</secondary_id>
    <secondary_id>PROM # 0025</secondary_id>
    <nct_id>NCT00566267</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet</brief_title>
  <acronym>LOCUST</acronym>
  <official_title>A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporal Michael J. Crescenz VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People who follow a low-carbohydrate diet typically experience a decrease in triglycerides
      and increase in HDL-C level, but fail to lower their LDL cholesterol (LDL-C). Such patients
      may require lipid-lowering therapy. Statins may not be the most effective strategy for
      patients on this diet, since they typically consume a greater amount of saturated fat and
      cholesterol. Absorbed cholesterol may contribute more to their circulating plasma LDL-C. We
      hypothesize that patients following a low carbohydrate diet would experience a significantly
      greater decrease in LDL-C by taking ezetimibe 10 mg, a drug that blocks cholesterol uptake in
      the intestine, in addition to simvastatin 20 mg, when compared to taking simvastatin 20 mg
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other lipid measures</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>8 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin 20 mg/ezetimibe</intervention_name>
    <description>see protocol</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Low carb diet plus simvastatin 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderately obese with hyperlipidemia

        Exclusion Criteria:

          -  Recent unstable heart or lung condition

          -  Current use of other lipid modifying drugs

          -  Hepatic disease

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick F Samaha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia VAMC</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <last_update_submitted>November 30, 2007</last_update_submitted>
  <last_update_submitted_qc>November 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2007</last_update_posted>
  <responsible_party>
    <name_title>Frederick F. Samaha, M.D.</name_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

